Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Credit

<ul><li>Abbott Laboratories has a highly diversified business model which helped the company survive the Covid-19 induced challenges and have a decent 2021.</li><li>The company has launched an innovative NeuroSphere virtual clinic which lets the patients communicate with physicians and get innovative treatments settings.</li><li>The company also received the US FDA approvals for CE mark for Navitor, amulet heart device, and heart replacement system.</li></ul>

Abbott Laboratories has a highly diversified business model which helped the company survive the Covid-19 induced challenges and have a decent 2021.The company has launched an innovative NeuroSphere virtual clinic which lets the patients communicate with physicians and get innovative treatments settings.The company also received the US FDA approvals for CE mark for Navitor, amulet heart device, and heart replacement system.

Abbott Laboratories: Detailed Credit Analysis & Financial Strength Evaluation Report

Equity Capital Markets

Abbott Laboratories / Equity Capital Markets

<ul><li>Abbott Laboratories reported a successful 2021 despite all pandemic-induced challenges on its business.</li><li>The company’s diversified business model is uniquely balanced over various dimensions, including geographic footprint, innovation cycles, and customer types, and it has a solid business mix.</li><li>Abbott has continued to grow its nutrition portfolio with various line extensions and new products, including Pediasure, Glucerna, and Similac 360.</li></ul>

Abbott Laboratories reported a successful 2021 despite all pandemic-induced challenges on its business.The company’s diversified business model is uniquely balanced over various dimensions, including geographic footprint, innovation cycles, and customer types, and it has a solid business mix.Abbott has continued to grow its nutrition portfolio with various line extensions and new products, including Pediasure, Glucerna, and Similac 360.

Abbott Laboratories: Financial & Price Forecasts

Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>Over the last one month, the U.S. healthcare sector remained mostly resilient to the inflation risk and gained 7.1% outperforming S&amp;P 500 index’s gain of 5%.  </li>
<li>Sound financials, high revenue visibility, low or no debt, and cash rich position are some of the reasons for the outperformance.</li>
<li>In this insight, we have handpicked top-quality healthcare sector bets from the S&amp;P 500 index and discussed about their growth stories.</li>
</ul>


Over the last one month, the U.S. healthcare sector remained mostly resilient to the inflation risk and gained 7.1% outperforming S&amp;P 500 index’s gain of 5%.  
Sound financials, high revenue visibility, low or no debt, and cash rich position are some of the reasons for the outperformance.
In this insight, we have handpicked top-quality healthcare sector bets from the S&amp;P 500 index and discussed about their growth stories.


U.S. Healthcare Sector: Ride Out Market Turmoil with High-Quality Large-Cap Ideas

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/phc-holdings-corp" target="_blank" data-smartkarma-citation="entities:34198:1" rel="noopener">PHC Holdings (6523 JP)</a> is a diversified healthcare company, which serves ~$25 billion broader end-market, of which global glucose monitoring is the largest end-market.</li>
<li>The company’s diabetes management business is the highest margin earning segment and is poised to grow through expanding presence in continuous glucose monitoring system.</li>
<li>PHC can be an early investment idea as a passive play on the fastest growing segment of the global diabetes management segment ahead of its global launch of next-generation CGM.</li>
</ul>



PHC Holdings (6523 JP) is a diversified healthcare company, which serves ~$25 billion broader end-market, of which global glucose monitoring is the largest end-market.
The company’s diabetes management business is the highest margin earning segment and is poised to grow through expanding presence in continuous glucose monitoring system.
PHC can be an early investment idea as a passive play on the fastest growing segment of the global diabetes management segment ahead of its global launch of next-generation CGM.


PHC Holdings (6523 JP): Eyeing a Bigger Pie of Global Diabetes Management Solution

Articles from Caixin Global, Caixin Global

Caixin Global

Articles from Caixin Global

Caixin is a media group dedicated to providing financial and business news through periodicals, online content, mobile apps, conferences, books and TV/video programs. Caixin aims to blaze a trail that helps traditional media prosper in the new media age through integrated multimedia platforms.

News from Caixin

Cross Asset Strategy

<ul>
<li>
In Depth: How the balance of power over Ukraine shattered overnight
</li>
<li>
Hong Kong can stock up on anti-Covid drugs to tackle omicron outbreak, top infectious disease expert says
</li>
<li>
ByteDance looks to exit securities business as fintech rules tighten
</li>
</ul>



In Depth: How the balance of power over Ukraine shattered overnight


Hong Kong can stock up on anti-Covid drugs to tackle omicron outbreak, top infectious disease expert says


ByteDance looks to exit securities business as fintech rules tighten



CX Daily: How the Balance of Power Over Ukraine Shattered Overnight

United States

Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company's products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Abbott Laboratories (ABT US)

Abbott Laboratories: Detailed Credit Analysis & Financial Strength Evaluation Report

Abbott Laboratories has a highly diversified business model which helped the company survive the Covid-19 induced challenges and have a decent...

Baptista Research

Abbott Laboratories: Financial & Price Forecasts

Abbott Laboratories reported a successful 2021 despite all pandemic-induced challenges on its business. The company’s diversified business model...

Baptista Research

U.S. Healthcare Sector: Ride Out Market Turmoil with High-Quality Large-Cap Ideas

Healthcare sector is expected to remain resilient to the inflation worry and outperform broader market in near-term. This insight highlights top...

Tina Banerjee

PHC Holdings (6523 JP): Eyeing a Bigger Pie of Global Diabetes Management Solution

Ahead of the global launch on Senseonics’ next-generation implantable CGM in Q2 2022, we are bullish on the long-term growth prospect of PHC.

Tina Banerjee

CX Daily: How the Balance of Power Over Ukraine Shattered Overnight

In Depth: How the balance of power over Ukraine shattered overnight. Hong Kong can stock up on anti-Covid drugs to tackle omicron outbreak, top...

Caixin Global

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)